We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Plant Health Care Plc | LSE:PHC | London | Ordinary Share | GB00B01JC540 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.12 | 3.46% | 3.59 | 3.30 | 3.86 | 3.62 | 3.44 | 3.56 | 675,665 | 16:35:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pesticides, Agric Chems, Nec | 11.77M | -9.48M | -0.0278 | -1.30 | 12.36M |
Date | Subject | Author | Discuss |
---|---|---|---|
30/8/2013 19:53 | Any further news/views on the sharp decline in the share price since May.On the surface it will look buy at 50p.Sure there are some powerful reasons for the decline. | 19wizard | |
26/6/2013 08:31 | Nothing specific but board shake up, full funded, great product , good investors have large holdings, directors bought stock... All that adds up to watch this space IMHO | pinkalltheway | |
26/6/2013 07:57 | Hi pink, have you any specific reason for thinking so? It's gone very quiet since the institutions finished their stake building. When are the results due? | bobdouthwaite | |
25/6/2013 19:27 | I think this space is worth watching VERY closely.. Upside potential | pinkalltheway | |
02/5/2013 09:21 | chairman makes first purchase of #50000. that's a good sign | cnx | |
17/1/2013 00:00 | HENDERSON INVESTMENTS NOW OVER 24% | cnx | |
02/11/2012 12:41 | ORA are keen, investing another £450k or so! RNS: ORA (Guernsey) Ltd and Richard Griffiths increase stake to 22.49% That explains the 450,730 trade on 31/10/12 @ 99p. | dlem | |
22/10/2012 17:10 | perhaps mr.henderson and m. griffiths know more than we know? | cnx | |
22/10/2012 13:05 | RNS: ORA (Guernsey) Ltd and Richard Griffiths increase stake to 21.65% from 18% | dlem | |
19/10/2012 15:14 | RNS: Henderson Global Investors cross 23% increasing stake to 23.81% from 21%. That only explains 1,410,332 of the 6,784,290 shares traded yesterday. | dlem | |
19/10/2012 08:50 | Yes I noticed the action, but only 1,000 at 85p were mine! The institutions have been building stakes for some months now as sales in the US appear to be taking off - at long last! | bobdouthwaite | |
19/10/2012 08:30 | 6,784,290 Shares Traded Yesterday! That must cross an RNS threshold. | dlem | |
09/10/2012 08:25 | mdrans1, it looks like you were correct regarding the directors being in a close period (which may have now ended with the issuing of the RNS below, unless there is more news pending). 9 October 2012 PLANT HEALTH CARE PLC ("Plant Health Care" or "the Company") Significant increase in USA crop area treated with foliar Harpin in 2012 Plant Health Care plc, a leading provider of innovative patent protected biological products to the global agriculture markets, is pleased to announce strong first sales of a novel approach to fungicide resistance management. Foliar sprays of ProAct (a Harpin-based product), in mixture with triazole fungicides, were applied on approximately 200,000 acres of crops in the USA this season, with outstanding results. These sales significantly exceeded the company's market share expectations in the first year of commercial sales. The combination is of particular relevance as there is increasing concern about resistance to the strobilurin fungicides currently on the market. Trials in 2011 conducted by the independent On-Farm Network in Iowa, USA, demonstrated that corn fields treated with a combination of ProAct and propiconazole fungicide delivered as good or better yield increases than those corn fields treated with BASF's market-leading Headline strobilurin-based product, which is marketed with plant health benefits. These findings, coupled with the Company's "Save the Strobies" marketing campaign, helped to drive sales of ProAct in mixture with triazoles up four times greater than the initial expectations of 50,000 treated acres. Agricultural scientists across the USA are already seeing strong evidence of resistance developing to strobilurin-based fungicides in the USA, as has already been witnessed in Europe and South America. The combination of Harpin with the post patent fungicide propiconazole, used in rotation with strobilurin based products, is the type of program that has been recommended by the Fungicide Resistance Action Committee, an organisation that aims to preserve the efficacy of fungicides on a global basis. John Brady, CEO of Plant Health Care, commented: "The strength of the uptake of ProAct and propiconazole in its initial year is a very exciting development for Plant Health Care. Used together as a rotation product on corn, soybeans and other susceptible crops has proven to be a highly effective method for farmers to mitigate the risk of diseases developing resistance to strobilurin fungicides, while also maintaining the disease control and yield potential they have become accustomed to receiving. This product provides farmers with a new set of options, which is the basis for our existing agreements with Arysta LifeScience and Makhteshim Agan Industries. I am delighted by the enthusiastic recognition that our product and marketing message is receiving." ~ Ends ~ | dlem | |
04/10/2012 17:13 | He my have inside information which prevents him from buying. | mdrans1 | |
04/10/2012 17:09 | The book 'We want real food' makes a very interesting read and love the fungi | spondon | |
04/10/2012 17:07 | I'm disappointed that Dr Richards has not yet purchased any shares in the company given his conclusion that Plant Health is at an "inflection" point, given his distinguished career and I assume high net worth status. 1st August 2012 Dr Richards said: "I am pleased to be joining Plant Health Care at an inflexion point in the Company's development. Dr Richards has had a distinguished career in the global agrochemical industry and is the non-executive Chairman of Arysta LifeScience Corporation ("Arysta LifeScience"), one of the world's largest privately-held agrochemical companies. Dr Richards joined Arysta LifeScience as Chief Operating Officer in 2003 and was Chief Executive Officer from 2004 to 2010. Under his leadership, Arysta LifeScience became one of the fastest-growing companies in the agrochemical industry. Arysta LifeScience was acquired by Permira Funds in 2008. Dr Richards, aged 58, previously worked in international management roles at Syngenta Crop Protection and at its predecessor companies Zeneca and ICI. He began his career at the UK Ministry of Agriculture, Fisheries and Food, having taken a doctorate from St John's College, Oxford. His other directorships include Dechra Pharmaceuticals plc, the international veterinary pharmaceuticals group listed in London. He is also non-executive chairman of Oxitec Ltd, the biotech company that is tackling dengue fever and agricultural pests, and a non-executive director of Cibus Global Inc, the seed technology company. | dlem | |
04/10/2012 16:58 | RNS Number : 1343M Plant Health Care PLC 13 September 2012 13 September 2012 Plant Health Care plc ("Plant Health Care" or "the Company") Significant increase in hectares being treated in the SA 2013 maize crop season Plant Health Care plc, a leading provider of novel patent protected biological products to the global agriculture markets, is pleased to announce that Insect Science, Ltd ("Insect Science"), its South African distributor for Harpin and Myconate, has reported significant progress with its Harpin foliar and Myconate seed treatment programmes for the 2013 maize crop season. In 2013, its second crop season, Insect Science is increasing the number of maize crop hectares it plans to treat with its foliar Harpin product by 567% to 100,000 hectares, or 4.5% of the total South African maize crop (2012: 15,000 hectares). Additionally it plans to increase the number of hectares treated with its Myconate seed treatment by 200% to 60,000 hectares or 2.7% of the total South African maize crop (2012: 20,000 hectares). John Brady, CEO of Plant Health Care, commented: "Insect Science has made substantial progress into our target market of foliar applied Harpin as well as seed treated with Myconate. In only its second year of the programme they have achieved significant market penetration in the very important maize crop in South Africa. We believe, based on very successful historical maize crop yield increases of approximately 6.5%, that we will continue to experience significant growth in the coming years." Charlie Bender, Marketing and Product Development Director of Insect Science, Ltd commented: "We are very pleased with the rapid growth we are experiencing with the Plant Health Care products. A significant portion of South African potatoes and pears crops are already treated with these products and we anticipate a similar growth pattern in the maize crop as well. Farmers have seen strong yield increases with this programme which has significantly enhanced their bottom lines." - ENDS - | dlem | |
20/8/2012 17:48 | Courtesy of Agrimoney: US drought hands fillip to Plant Health Care | bobdouthwaite | |
14/8/2012 06:42 | Now we know where Mr Quested might have acquired shares from in July. | parvez | |
01/8/2012 11:39 | Dr Richards said: "I am pleased to be joining Plant Health Care at an inflexion point in the Company's development. RNS Number : 0562J Plant Health Care PLC 01 August 2012 1 August 2012 Plant Health Care plc ("Plant Health Care" or "the Company") Appointment of Chairman Industry leader Dr Christopher Richards is Plant Health Care's new Chairman Plant Health Care plc, a leading provider of naturally-derived products to the global agriculture markets, is pleased to announce the appointment of Dr Christopher Richards as an independent director and non-executive Chairman of the Company, with immediate effect. Dr Richards has had a distinguished career in the global agrochemical industry and is the non-executive Chairman of Arysta LifeScience Corporation ("Arysta LifeScience"), one of the world's largest privately-held agrochemical companies. Dr Richards joined Arysta LifeScience as Chief Operating Officer in 2003 and was Chief Executive Officer from 2004 to 2010. Under his leadership, Arysta LifeScience became one of the fastest-growing companies in the agrochemical industry. Arysta LifeScience was acquired by Permira Funds in 2008. Dr Richards, aged 58, previously worked in international management roles at Syngenta Crop Protection and at its predecessor companies Zeneca and ICI. He began his career at the UK Ministry of Agriculture, Fisheries and Food, having taken a doctorate from St John's College, Oxford. His other directorships include Dechra Pharmaceuticals plc, the international veterinary pharmaceuticals group listed in London. He is also non-executive chairman of Oxitec Ltd, the biotech company that is tackling dengue fever and agricultural pests, and a non-executive director of Cibus Global Inc, the seed technology company. Following the appointment of Dr Richards, Sam Wauchope steps down as Interim Chairman and returns to his previous role as Senior Independent Director. Dr Richards said: "I am pleased to be joining Plant Health Care at an inflexion point in the Company's development. Plant Health Care has demonstrated that its technology can significantly improve the yields of many important crops, a benefit that is of considerable commercial potential. I look forward to helping John Brady and his management team realise Plant Health Care's promise." John Brady, CEO of Plant Health Care, said: "We are delighted that Chris has joined us. He brings with him a wealth of experience and I look forward to working with him closely as we enter a very exciting period for the Company." Save for the information disclosed above there is no other information to be disclosed under Rule 17 or Schedule Two, paragraph (g) of the AIM Rules for Companies in relation to Dr Christopher Gareth Joseph Richards' appointment as a director of the Company other than as follows: Current Directorships Past Directorships Arysta LifeScience Corporation Arysta LifeScience U.K Limited Talestris Ltd Arysta LifeScience North America, LLC (formerly Arysta LifeScience North America Corporation, and formerly known as Arvesta Corporation) Talestris Latinoamerica Inc Arvesta Corporation Talestris Industrial Inc ANESA S.A Talestris Colombia SAS Callietha Investments (Pty) Ltd Fundicom SA Volcano Agroscience (Pty) Ltd Bio Products Laboratory Ltd Arysta LifeScience Holdings SA (Pty) Ltd (formerly known as Arysta LifeScience South Africa (Pty) Ltd) Richards Underwriting Limited Arysta LifeScience Global Holding Pte. Ltd. (liquidated 2008) Dechra plc Cibus Global Inc. Oxitec Ltd Ashridge Court Partnership - ENDS - | dlem | |
30/7/2012 13:57 | Mr Quested (UAE based businessman) seems like a seasoned investor and has following other holdings: look slike a man to follows | parvez | |
27/7/2012 13:19 | fantastic announcement and great chart. | parvez | |
20/7/2012 12:59 | 74.9% of shares held by 9 Institutional Shareholders, hence the lack of share liquidity and spikes on low volume. The top 4 Institutional Shareholders control 51.6% That's not many calls to make to agree a takeover. The identity and percentage holdings of any significant shareholders - On 17 July 2012, the Company had been notified of the following holdings representing in excess of 3% of the Company's ordinary shares: Henderson Global Investors Limited 11,098,593 shares 20.83% ORA (Guernsey) Limited 9,088,853 shares 17.09% Boulder River Capital Corporation 4,500,000 shares 8.47% Credit Suisse 2,727,290 5.21% Aviva plc & its subsidiaries 2,588,938 shares 4.88% Generation Investment Management LLP 2,355,000 5.26% Branco Weiss 2,196,954 5.24% Universities Superannuation Scheme Limited 2,102,500 3.9% Funds managed by AXA SA for Framlington 1,804,463 4.02% *The percentages shown are based on the issued share capital as at the date of notification. | dlem | |
20/7/2012 12:56 | 2012: Sees an interesting and untypical flurry of activity and interest in PHC RNS ANNOUNCEMENTS SINCE FEB 2012: 27/02/2012 Encouraging Final results 27/02/2012 Change of Adviser 21/02/2012 ORA (Guernsey) Limited increase from 10%-12% (The principal activity of the company is the growth and development of businesses in which ORA has or acquires a significant shareholding minority or majority shareholding). 23/03/2012 ORA (Guernsey) Limited increase from 12%-13% 05/04/2012 Agreement with MANA Crop Protection 13/04/2012 Chairman resigns suddenly (and Prior to AGM). 17/04/2012 Allotment of shares to directors. 18/04/2012 Henderson Global Investors Crossed below 16% 20/04/2012 AGM Resolutions passed (so Institutional Investors must be content). 20/04/2012 ORA (Guernsey) Limited increase from 13%-14% 25/04/2012 ORA (Guernsey) Limited crossed 16% 27/04/2012 Research Agreement with Arysta LifeScience 01/05/2012 Confirmation of Voting rights 03/05/2012 ORA (Guernsey) Limited crossed 17% 17/05/2012 Research co-operation with University of Arkansas 28/06/2012 Henderson Global Investors Crossed above 16% 17/07/2012 Henderson Global Investors Crossed above 19% 18/07/2012 Henderson Global Investors Crossed above 20% Substantial and untypical share volumes throughout this period. | dlem | |
20/7/2012 09:59 | Also been a bit of M&A in the sector recently. | vega44 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions